Changsha Jingyi Pharmaceutical Technology Co., Ltd. was established in August 2010. It is a CRO enterprise that provides full chain services for new drug research and development for pharmaceutical enterprises and research institutions. The company currently has over 1300 multidisciplinary professional and technical personnel led by scientists, with doctoral and senior engineers as the core (including controlling and joint-stock companies), and a modern research and development laboratory area of over 25000 square meters.

The company's business scope covers the entire process of drug development, including drug discovery and drug efficacy evaluation, pharmaceutical research (CMC), non clinical research (GLP), analytical testing (biology/chemistry), clinical research (GCP), CDMO (raw materials/formulations), and registration (domestic/international). The company has established technical platforms for active pharmaceutical ingredients, topical formulations, sustained-release and compound formulations, and pediatric formulations, as well as non clinical research, biological analysis, chemical analysis, and Phase I/II/III clinical services. Innovative formulations and clinical research are the company's core competitive advantages. In the field of topical formulations, the company has the largest domestic research team and a CDMO production line for all topical formulations.

Enterprise Services/Technology:

Provide a full chain solution for new drug research and development: drug discovery and drug efficacy evaluation, pharmaceutical research (CMC), non clinical research (GLP), analytical testing (biology/chemistry), clinical research (GCP), CDMO (raw materials and formulations), registration application (domestic/international)